Osee Behuhuma

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Anna Turkova, Ellen White, Cissy Kityo et al. · UCL Discovery (University College London) · 2021 · 103 citations

Pharmacy, Pediatrics, Pharmacotherapy +16

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

Cecilia L. Moore, Anna Turkova, Hilda Mujuru et al. · BMC Infectious Diseases · 2021 · 42 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Machine learning outperformed logistic regression classification even with limit sample size: A model to predict pediatric HIV mortality and clinical progression to AIDS

Sara Domínguez‐Rodríguez, Miquel Serna‐Pascual, Andrea Oletto et al. · PLoS ONE · 2022 · 32 citations · Full text

Computing, Child Health, Machine Learning +14

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Pauline Amuge, Abbas Lugemwa, Ben Wynne et al. · The Lancet HIV · 2022 · 31 citations · Full text

Pharmacy, Infectious Diseases, Pediatrics +15

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man K. Chan et al. · The Lancet HIV · 2022 · 24 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17